Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

a study on Myasthenia Gravis

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
completion around

Description

Summary

This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

Official Title

Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)

Keywords

Myasthenia Gravis, Generalized, Descartes-08, CART, CAR-T, Autoimmune, Auto-antibody, Auto antibody, chimeric antigen receptor, T cells, MG, gMG, Myasthenia Gravis, Generalized Myasthenia gravis, Muscle Weakness

Eligibility

You can join if…

Open to people ages 18 years and up

  • Patient must be at least 18 years of age.
  • Patient must have Generalized Myasthenia Gravis at the time of screening.
  • Concomitant immunosuppressive drugs must be deemed necessary by the investigator.
  • Seronegative Patients are included

You CAN'T join if...

  • Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.
  • Patient is pregnant or lactating.

Locations

  • University of California Irvine accepting new patients
    Irvine California 92697 United States
  • Profound Research accepting new patients
    Carlsbad California 92011 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Cartesian Therapeutics
ID
NCT04146051
Phase
Phase 2 Myasthenia Gravis Research Study
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated